How do we manage t(11;14) plasma cell disorders with venetoclax?

Chakraborty, R., Bhutani, D., & Lentzsch, S. (2022). How do we manage t(11;14) plasma cell disorders with venetoclax? British Journal of Haematology, 199(1), 31–39. Portico. https://doi.org/10.1111/bjh.18243
Authors:
Rajshekhar Chakraborty
Divaya Bhutani
Suzanne Lentzsch
Affiliated Authors:
Rajshekhar Chakraborty
Divaya Bhutani
Suzanne Lentzsch
Columbia Affiliation:
Subjects:
Antineoplastic Agents (MeSH)
Paraproteinemias (MeSH)
Author Keywords:
multiple myeloma
t(11
14)
venetoclax
t(11;14)
elink
Publication Type:
Article
Unique ID:
10.1111/bjh.18243
PMID:
35594184
DOI:
10.1111/bjh.18243
Journal:
British Journal of Haematology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record

Record Created: